- Home
- FSI vs RVPHW Comparison
FSI vs RVPHW Comparison
Compare FSI & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSI
- RVPHW
- Stock Information
- Founded
- FSI 1991
- RVPHW N/A
- Country
- FSI Canada
- RVPHW United States
- Employees
- FSI N/A
- RVPHW 15
- Industry
- FSI Recreational Games/Products/Toys
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- FSI Consumer Discretionary
- RVPHW Health Care
- Exchange
- FSI Nasdaq
- RVPHW Nasdaq
- Market Cap
- FSI N/A
- RVPHW N/A
- IPO Year
- FSI 1999
- RVPHW 2018
- Fundamental
- Price
- FSI $3.94
- RVPHW $0.21
- Analyst Decision
- FSI
- RVPHW
- Analyst Count
- FSI 0
- RVPHW 0
- Target Price
- FSI N/A
- RVPHW N/A
- AVG Volume (30 Days)
- FSI 44.7K
- RVPHW N/A
- Earning Date
- FSI 11-14-2024
- RVPHW N/A
- Dividend Yield
- FSI 2.53%
- RVPHW N/A
- EPS Growth
- FSI 11.03
- RVPHW N/A
- EPS
- FSI 0.33
- RVPHW N/A
- Revenue
- FSI $38,493,925.00
- RVPHW N/A
- Revenue This Year
- FSI $11.70
- RVPHW N/A
- Revenue Next Year
- FSI $12.51
- RVPHW N/A
- P/E Ratio
- FSI $11.96
- RVPHW N/A
- Revenue Growth
- FSI N/A
- RVPHW N/A
- 52 Week Low
- FSI $1.50
- RVPHW N/A
- 52 Week High
- FSI $4.44
- RVPHW N/A
- Technical
- Relative Strength Index (RSI)
- FSI 50.76
- RVPHW N/A
- Support Level
- FSI $3.72
- RVPHW N/A
- Resistance Level
- FSI $4.22
- RVPHW N/A
- Average True Range (ATR)
- FSI 0.22
- RVPHW 0.00
- MACD
- FSI -0.04
- RVPHW 0.00
- Stochastic Oscillator
- FSI 31.94
- RVPHW 0.00
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.